Delving into the Latest Updates on Thioguanine with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2-Amino 6MP, 2-Amino-1,7-dihydro-6H-purine-6-thione, 2-Amino-6-mercaptopurine

+ [26]

Target

DNA

Mechanism

DNA inhibitors(DNA inhibitors)

Therapeutic Areas

NeoplasmsImmune System DiseasesHemic and Lymphatic Diseases

Active Indication

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaPhiladelphia chromosome positive chronic myelogenous leukemia

Inactive Indication-

Originator Organization

Aspen Pharmacare Holdings Ltd.

Active Organization

Waylis Therapeutics LLCShanghai Donghai Pharmaceutical Co., Ltd.

Inactive Organization

Only For Children Pharmaceuticals SA

Drug Highest PhaseApproved

First Approval Date

US (18 Jan 1966),

Acute Myeloid LeukemiaPhiladelphia chromosome positive chronic myelogenous leukemia

RegulationOrphan Drug (EU)

Login to view timeline

Structure

Molecular FormulaC5H5N5S

InChIKeyWYWHKKSPHMUBEB-UHFFFAOYSA-N

CAS Registry154-42-7

This phase III trial compares the effect of the combination of blinatumomab with dasatinib and standard chemotherapy versus dasatinib and standard chemotherapy for treating patients with Philadelphia chromosome positive (PH+) or Philadelphia chromosome-like (Ph-Like) ABL-class B-Cell acute lymphoblastic leukemia (B-ALL). Blinatumomab is a bispecific antibody that binds to two different proteins-one on the surface of cancer cells and one on the surface of cells in the immune system. An antibody is a protein made by the immune system to help fight infections and other harmful processes/cells/molecules. Blinatumomab may bind to the cancer cell and a T cell (which plays a key role in the immune system's fighting response) at the same time. Blinatumomab may strengthen the immune system's ability to fight cancer cells by activating the body's own immune cells to destroy the tumor. Dasatinib is in a class of medications called tyrosine kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply, which may help keep cancer cells from growing. Giving blinatumomab and dasatinib in combination with standard chemotherapy may work better in treating patients with PH+ or Ph-Like ABL-class B-ALL compared to dasatinib and chemotherapy alone.

Start Date28 Feb 2025

Sponsor / Collaborator

National Cancer Institute

NCT06317662 / Not yet recruitingPhase 2IIT

A Phase 2 Study of Blinatumomab in Combination With Chemotherapy for Infants With Newly Diagnosed Acute Lymphoblastic Leukemia With Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged [R]) or without a KMT2A gene rearrangement (KMT2A-germline [G]). Venetoclax is in a class of medications called B-cell lymphoma-2 (Bcl-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Blinatumomab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Chemotherapy drugs work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding venetoclax and/or blinatumomab to standard chemotherapy may be more effective at treating patients with ALL than standard chemotherapy alone, but it may also cause more side effects. This clinical trial evaluates the safety and effectiveness of adding venetoclax and/or blinatumomab to chemotherapy for the treatment of infants with KMT2A-R or KMT2A-G ALL.

Start Date26 Jan 2025

Sponsor / Collaborator

National Cancer Institute

NCT06533748 / Not yet recruitingPhase 2IIT

SJALL23H: Combination Antigen-Directed Induction Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma

This is a Phase II clinical trial testing the use of two antigen-directed therapies, inotuzumab and blinatumomab, as part of induction therapy for children and young adults with newly diagnosed B-cell precursor acute lymphoblastic leukemia and lymphoma.
Primary Objective
* To assess if the flow-cytometry assessed MRD-negative remission rate following an immunotherapy-based Induction in NCI-high risk patients without favorable genetic features is higher than the results of similar patients treated on AALL1131.
Secondary Objectives
* To compare flow-cytometry assessed MRD-negative rates at the end of Induction for patients treated with this therapy compared to similar patients treated on TOT17.
* To compare the rate of significant toxicities in patients treated with this therapy to those treated with standard-risk therapy on TOT17.
* To assess the event free and overall survival of patients treated with this therapy.

Start Date01 Nov 2024

Sponsor / Collaborator

St. Jude Children's Research Hospital, Inc.

[+2]

100 Clinical Results associated with Thioguanine

Login to view more data

100 Translational Medicine associated with Thioguanine

Login to view more data

100 Patents (Medical) associated with Thioguanine

Login to view more data

3,884

Literatures (Medical) associated with Thioguanine

01 Feb 2025·Journal of Environmental Sciences

Mercury contents and potential exposure risk of rice-containing food products

Article

Author: Liu, Ziyan ; Wang, Yingjun ; Zhang, Yaqi ; Cai, Yong ; Ji, Xiaomeng ; Wang, Xin

Mercury (Hg), especially methylmercury (MeHg), accumulation in rice grain due to rice paddy possessing conditions conducive to Hg methylation has led to human Hg exposure through consumption of rice-based daily meals. In addition to being a food staple, rice is widely used as a raw material to produce a vast variety of processed food products. Little is known about Hg levels in snacking rice-food products and potential Hg exposure from consumption of them, besides previous studies on infant rice cereals. Aiming to provide complementary information for a more complete assessment on Hg exposure risk originated from Hg-containing rice, this study determined total Hg (THg) and MeHg levels in 195 rice-containing and rice-free processed food products covering all major types of snack foods marketed in China and the estimated daily intake (EDI) of dietary Hg from the consumption of these foods. The results clearly showed THg and MeHg contents in rice-containing foods were significantly higher than rice-free products, suggesting the transfer of Hg and MeHg from the rice to the end products, even after manufacturing processes. Moreover, significant positive correlations were observed between THg, MeHg, or MeHg/THg ratio and rice content for samples containing multiple grains as ingredients, further indicating the deciding role of rice for Hg levels in the end food products. Although the EDI of THg and MeHg via rice-based food products were relatively low compared to the reference dose, it should be considered these snacking food products would contribute additive Hg intake outside of the daily regular meals.

31 Dec 2024·Virulence

Immunosuppressants exert antiviral effects against influenza A(H1N1)pdm09 virus via inhibition of nucleic acid synthesis, mRNA splicing, and protein stability

Article

Author: Zhang, Jiayou ; Yang, Xuanye ; Wang, Xin ; Duan, Kai ; Yang, Xiao-Ming ; Pu, Feiyang ; Nian, Xuanxuan ; Ma, Xiao-Xia ; Ma, Zhongren ; Feng, Xili

Influenza A virus (IAV) poses a threat to patients receiving immunosuppressive medications since they are more susceptible to infection with severe symptoms, and even death. Understanding the direct effects of immunosuppressants on IAV infection is critical for optimizing immunosuppression in these patients who are infected or at risk of influenza virus infection. We profiled the effects of 10 immunosuppressants, explored the antiviral mechanisms of immunosuppressants, and demonstrated the combined effects of immunosuppressants with the antiviral drug oseltamivir in IAV-infected cell models. We found that mycophenolic acid (MPA) strongly inhibits viral RNA replication via depleting cellular guanosine pool. Treatment with 6-Thioguanine (6-TG) promoted viral protein degradation through a proteasomal pathway. Filgotinib blocked mRNA splicing of matrix protein 2, resulting in decreased viral particle assembly. Furthermore, combined treatment with immunosuppressants and oseltamivir inhibits IAV viral particle production in an additive or synergic manner. Our results suggest that MPA, 6-TG, and filgotinib could be the preferential choices for patients who must take immunosuppressants but are at risk of influenza virus infection.

01 Dec 2024·Science of The Total Environment

Differences in mercury (THg) levels in Brown booby (Sula leucogaster) feathers from two environmentally distinct Brazilian archipelagos

Article

Author: Gonçalves, Edson Moreira ; Costa Ribeiro, Bianca ; Ribeito, Bianca Costa ; Benemann, Victória Renata Fontoura ; Gonçalves Moreira, Edson ; Petry, Maria Virginia ; Fontoura Benemann, Victória Renata

Mercury pollution is a matter of global concern due to its detrimental effects on ecosystems and human well-being. Seabirds generally occupy high levels within trophic chains and are often used as valuable indicators of marine pollution, including mercury contamination. We examined the concentrations of total mercury (THg) in the ventral feathers of Brown boobies (Sula leucogaster) from two distinct Brazilian archipelagos: one coastal and subtropical (Moleques do Sul) and one tropical and oceanic (São Pedro and São Paulo). We hypothesized that there would be differentiation in mercury levels between these archipelagos due to differences in geographical location and environmental conditions, where higher Hg levels would be found in Brown boobies from the coastal one since they are more exposed to anthropogenic sources from the continent. Additionally, we also investigated whether there were any differences in mercury levels based on sex and age. We found significantly higher THg levels in Brown boobies from São Pedro and São Paulo compared to those from Moleques do Sul, indicating differential levels of exposure to mercury sources. No significant differences between sexes or age classes, although juvenile individuals showed the lowest values. We suggest that the THg higher levels found in individuals from São Pedro e São Paulo can be due to the geological peculiarities of this archipelago, formed by mantle peridotites considered mercury hotspots. Our findings emphasize the importance of considering spatial and environmental factors in mercury biomonitoring and highlight the potential use of seabird feathers as a proxy for mercury contamination in marine environments.

100 Deals associated with Thioguanine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06109	Thioguanine	L01BB03	DB00352

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	CN	Shanghai Donghai Pharmaceutical Co., Ltd.	01 Jan 1995
Acute Myeloid Leukemia	US	Waylis Therapeutics LLC	18 Jan 1966
Philadelphia chromosome positive chronic myelogenous leukemia	US	Waylis Therapeutics LLC	18 Jan 1966

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Acute Lymphoblastic Leukemia	Preclinical	FR	Only For Children Pharmaceuticals SA	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02101853 (AALL1331, CTgov)	Phase 3	Recurrent B Acute Lymphoblastic Leukemia \| Pre B-cell acute lymphoblastic leukemia	669	Asparaginase+Etoposide+cyclophosphamide+Leucovorin Calcium+pegaspargase+Therapeutic Hydrocortisone+Mitoxantrone+Dexamethasone+Vincristine Sulfate+Methotrexate+Cytarabine (Arm A (HR and IR Control))	osclpohxxh(vswenanmzk) = zwygetnfml gylilfawoc (aokpnrqodn, mlushpgcuq - zwlvxyejbp) View more	-	06 Dec 2022
				Pharmacological Study+Therapeutic Hydrocortisone+blinatumomab+Dexamethasone+Methotrexate+Cytarabine (Arm B (HR and IR Blinatumomab))	osclpohxxh(vswenanmzk) = goddfribcw gylilfawoc (aokpnrqodn, eyinjitdqs - kugiixnhid) View more
IAS2022	Not Applicable	-	-	6 months of daily isoniazid (6H)	uenfqvedyo(uladaiubcf) = zaqufnubvn rvqbbivlof (opakcmtdxl, 4 - 15)	-	01 Jan 2022
				3 months of weekly rifapentine/isoniazid (3HP)	uenfqvedyo(uladaiubcf) = cvdsogopiq rvqbbivlof (opakcmtdxl, 0 - 6)
NCT02828358 (AALL15P1, CTgov)	Phase 2	Pre B-cell acute lymphoblastic leukemia \| Mixed phenotype acute leukemia	78	HC+cyclophosphamide+PEG+leucovorin calcium+thioguanine+6-MP+dexamethasone+MTX+vincristine sulfate+daunorubicin hydrochloride+AZACITIDINE (AZA)+ARA-C (KMT2A-Rearranged)	edqutezuxy(ysvvhwvuqx) = yovifuvrns nlmqnhngmn (aduxpzbctx, lwfxqgovsy - fepexlptus) View more	-	26 Oct 2021
				cytarabine (ARA-C)+prednisolone+dexamethasone+vincristine sulfate+Methotrexate+daunorubicin hydrochloride (KMT2A-Germline)	gujehskcff(psqjgpfqmz) = eovxqfbxpv sfroxxvpff (gygklxlqat, vtxjqdqzuc - otglpbchlq) View more
NCT00439296 (CTgov)	Phase 1/2	Recurrent Adult Acute Lymphoblastic Leukemia	9	PEG-asparaginase+CYCLOPHOSPHAMIDE+doxorubicin+6-thioguanine+Dexamethasone+Methotrexate+Cytarabine+ABT-751 (Dose Level 1)	djwzdfsgyf(ydlqvnapef) = ewbzqairlm emibyiufsj (mnfyifolmu, edrrrersjo - jhtqhckdvf) View more	-	09 Sep 2020
				PEG-asparaginase+CYCLOPHOSPHAMIDE+doxorubicin+6-thioguanine+Dexamethasone+Methotrexate+Cytarabine+ABT-751 (Dose Level 0)	djwzdfsgyf(ydlqvnapef) = fjknpxvpbl emibyiufsj (mnfyifolmu, phjyxqmkqi - jrdtaidfsw) View more
NCT00866749 (CTgov)	Phase 2	Acute Lymphoblastic Leukemia	120	PEG-asparaginase+Cyclophosphamide+doxorubicin+Thioguanine+Mercaptopurine+Methotrexate+Vincristine+cytarabine+Daunorubicin	ozuyptpixp(dnsuusbneg) = wkchgnysvw srsxitzwbr (fjuozfnwhp, kxmadshbsq - kfyqooennz) View more	-	10 Sep 2019
NCT00588536 (CTgov)	Phase 2	Histiocytosis, Langerhans-Cell	5	Leucovorin+6-TG+MTX	mxzvdhchca(sekzynzldu) = mvgchzysbz tuzhvbfqhh (kvgukqgdwb, cnkzncluzq - fxjwlcoaou) View more	-	04 May 2015
NCT00369317 (AAML0431, CTgov)	Phase 3	Secondary Myelodysplastic Syndrome \| Acute Eosinophilic Leukemia \| Childhood Acute Monoblastic Leukemia and Acute Monocytic Leukemia \| untreated pediatric acute nonlymphocytic leukemia \| Acute Myelomonocytic Leukemia \| Acute Erythroblastic Leukemia \| Acute Basophilic Leukemia \| Down Syndrome \| Acute Megakaryoblastic Leukemia	205	laboratory biomarker analysis+etoposide+asparaginase+thioguanine+Cytarabine+daunorubicin hydrochloride	cotqbbatvp(nndsgrecyh) = xwkluydptl fcsourbpxl (aycpsyxtjs, eetyvewlvw - ruxlbojfgv) View more	-	13 Jan 2015
NCT00176462 (CTgov)	Phase 2	Acute Lymphoblastic Leukemia	60	Daunomycin+Cyclophosphamide+leucovorin+Hydrocortisone+6-thioguanine+aminopterin+6-mercaptopurine+dexamethasone+Vincristine+Methotrexate+Cytarabine+L-Asparaginase (Arm 2 High Risk)	eruesbuggn(dzuaxuehbt) = saedcoaano kpolvhwhcl (qjnrdczgnn, bnkkpiftxo - bajkodqkyr) View more	-	09 Jun 2014
				Daunomycin+leucovorin+Hydrocortisone+6-mercaptopurine+dexamethasone+Methotrexate+Vincristine+Cytarabine+L-Asparaginase (Arm 1 Standard Risk)	ivwzwrcyjd(gmmpuuytsg) = ncbkjgarwk atrgftoanp (tbehmladjb, bcdtcufwju - gvqtpxaozh) View more
NCT00004228 (CTgov)	Phase 3	Adult Lymphoblastic Lymphoma	393	asparaginase+Cyclophosphamide+prednisone+doxorubicin hydrochloride+thioguanine+mercaptopurine+dexamethasone+vincristine sulfate+methotrexate+cytarabine+daunorubicin hydrochloride (A0 (Localized Disease Stg I/II) Modified CCG BFM)	dprtxfqrub(miiubcoarz) = miqlqbjgdy kaoxcccttt (lkxbtqldky, ogzwzccyvh - lxltrlvljb) View more	-	05 Dec 2013
				asparaginase+Cyclophosphamide+prednisone+doxorubicin hydrochloride+thioguanine+mercaptopurine+dexamethasone+vincristine sulfate+methotrexate+cytarabine+daunorubicin hydrochloride (A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens)	dprtxfqrub(miiubcoarz) = wwiebtvzyy kaoxcccttt (lkxbtqldky, hicwzalalz - vgjwmclhwn) View more
NCT00109837 (S0333, CTgov)	Phase 2	Acute Lymphoblastic Leukemia \| Adult Acute Myeloblastic Leukemia	79	GCSF+Dex+Adriamycin+Vincristine (Treatment)	qdeepahwqm(ddwtravspm) = xharhcazge wyqayrxjmn (ldcprzzwvm, jiaxorslyd - htayxywqyp)	-	23 Aug 2012
				PEG- L-asparaginase+daunorubicin+prednisone+allopurinol+vincristine (Induction)	bbfjnfkfrd(xpzkllvyop) = csmqjkhzho txubptxmvl (vvniedkutl, vtjprtyhqq - qmgtapjmkx) View more